Hemispherx Biopharma (HEB) Receives U.S. Patent Office Notification of Two New Patents Granted for Alferon(R) LDO
1/17/2012 9:51:10 AM
PHILADELPHIA, Jan. 17, 2012 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company" or "Hemispherx") announced today the granting of two new United States Patents for the use of Alferon® LDO (Low Dose Oral Interferon Alfa-n3). Alferon® LDO (Human Leukocyte Derived) is an experimental low-dose, oral liquid formulation of Natural Alpha Interferon, and, like Alferon N Injection®, should not cause antibody formation, which is a known problem with recombinant interferon. Alferon® LDO is an experimental immunotherapeutic believed to work by stimulating an immune cascade response in the cells of the mouth and throat, enabling it to bolster systemic immune response through the entire body by absorption through the oral mucosa. Oral interferon could be economically feasible for patients and logistically manageable in development programs in third-world countries primarily affected by influenza and other emerging viruses. Oral administration of Alferon® LDO, with its anticipated affordability, low toxicity, expected non-production of antibodies, and broad range of potential bioactivity, could be a breakthrough treatment for prevention for viral diseases including influenza.